Pediatric cancer refers to cancers diagnosed in children and adolescents, typically from birth through age 19. It is rare compared to adult cancer, but it remains one of the leading causes of disease-related death in children. The overall five-year survival rate now ranges from about 83% to 88% depending on the child’s age at diagnosis, a dramatic improvement from just a few decades ago.
The Most Common Types
The three most frequent categories of childhood cancer are leukemias (cancers of the blood and bone marrow), brain and central nervous system tumors, and lymphomas (cancers of the immune system’s lymph nodes). Together, these account for the majority of pediatric diagnoses.
Among leukemias, acute lymphoblastic leukemia (ALL) is by far the most common childhood cancer. It tends to respond well to treatment, especially in younger children: the five-year survival rate for children ages 1 to 4 with ALL is 96%. Brain tumors are the second most common group and vary widely in severity. Some are highly treatable, while others, like diffuse intrinsic pontine glioma, carry a survival rate of only about 10% at two years. Non-Hodgkin lymphoma has also seen major gains, with the five-year survival rate climbing from 43% in 1975 to over 91% today.
How Childhood Cancer Differs From Adult Cancer
Pediatric cancers are biologically distinct from cancers in adults. Adult cancers typically develop after decades of accumulated DNA damage from things like smoking, sun exposure, or aging. Children haven’t lived long enough for that kind of damage to pile up, so their cancers arise through different mechanisms, often involving errors in normal cell growth and development rather than years of environmental wear.
This distinction matters for treatment. Therapies designed around adult cancer biology don’t always translate well to children. Pediatric tumors tend to have far fewer genetic mutations than adult tumors, but the mutations they do carry often involve genes that control how cells grow and differentiate during development. That’s one reason childhood cancers are increasingly treated as their own category, with research focused specifically on the biology driving them.
Causes and Risk Factors
For most children diagnosed with cancer, there is no identifiable external cause. Apart from high-dose radiation and prior chemotherapy, no environmental exposures have been definitively established as causes of childhood cancer. Studies examining parental diet, smoking, alcohol use, pesticide exposure, and air pollution have generally come back with null or only slightly elevated results. This can be frustrating for families looking for answers, but it reflects the reality that childhood cancer is not a lifestyle disease.
Inherited genetic syndromes account for roughly 5% to 10% of childhood cancers. These involve specific mutations passed from parent to child that significantly raise cancer risk. Beyond those rare syndromes, several inherent factors show consistent associations. Higher birth weight correlates with increased risk for several childhood cancers, including leukemia, brain tumors, and kidney tumors (Wilms tumor). Advanced parental age at birth is also linked to higher risk, with studies showing a 6% to 15% increase per five years of maternal age across multiple cancer types. Children born with structural birth defects have about three times the average risk of developing cancer.
Warning Signs to Recognize
Childhood cancer symptoms often mimic common childhood illnesses, which can delay diagnosis. The key difference is persistence. Symptoms that don’t resolve on a normal timeline, or that worsen steadily, deserve closer attention.
For blood cancers like leukemia and lymphoma, warning signs include unexplained prolonged paleness, fatigue, persistent fevers, loss of appetite, weight loss, swollen lymph nodes, and unusual bruising or bleeding. Brain and spinal cord tumors may cause new or persistent morning headaches paired with vomiting, changes in balance or coordination, vision problems, or back pain. A visible mass in the abdomen or soft tissues, or bone pain that wakes a child at night, can signal solid tumors like neuroblastoma, Wilms tumor, or bone cancers. A white glow in the pupil of a child’s eye (sometimes caught in flash photographs) is a hallmark of retinoblastoma, a cancer of the eye.
Less obvious signs include unexplained growth arrest, early or delayed puberty, and excessive thirst with frequent urination, which can point to tumors affecting hormone-producing glands.
Survival Rates by Age
Based on data from 2013 to 2019, the five-year survival rates for pediatric cancer break down by age group:
- Under 1 year: 83.2%
- Ages 1 to 4: 87.8%
- Ages 5 to 9: 85.7%
- Ages 10 to 14: 85.5%
- Ages 15 to 19: 87.3%
These numbers represent enormous progress. The five-year survival rate for ALL, the most common childhood cancer, was 57% in 1975. Today it exceeds 92%. Similar improvements have occurred across most pediatric cancer types, driven by better chemotherapy combinations, refined radiation techniques, and more precise risk classification that matches treatment intensity to the aggressiveness of the disease.
Precision Medicine for High-Risk Cases
For the roughly 20% to 30% of children whose cancers are considered high-risk (meaning their expected cure rate with standard treatment falls below 30%), precision medicine is changing the landscape. A major trial called PRISM used comprehensive genetic profiling of tumors, including whole-genome sequencing, to find molecular vulnerabilities that could be targeted with specific drugs.
Among 384 children with high-risk cancers enrolled in the trial, precision-guided treatment produced a 36% response rate and more than doubled two-year progression-free survival compared to standard care (26% versus 12%). The approach worked best when treatments targeted specific genetic fusions within the tumor or when therapy began before the disease had progressed further. About three-quarters of precision-guided recommendations involved a single targeted drug rather than complex multi-drug regimens, making treatment more focused and, in many cases, more tolerable.
Long-Term Effects of Treatment
With survival rates now exceeding 85% for most age groups, the population of childhood cancer survivors is growing, and so is awareness of the health challenges they face later in life. Between 60% and 90% of survivors develop at least one chronic health condition related to their treatment. For 20% to 80%, those conditions become severe or life-threatening during adulthood.
Heart problems are among the most significant concerns. Certain chemotherapy drugs and chest radiation can damage the heart muscle, leading to heart failure, valve problems, or coronary artery disease years or even decades after treatment ends. Survivors also face an elevated risk of developing a second, unrelated cancer later in life, including breast cancer, thyroid cancer, and skin cancer. This risk is one of the leading causes of death among long-term survivors outside of their original cancer returning.
Hormonal disruptions are common as well. Radiation to the brain can damage the glands that regulate growth, puberty, and metabolism, leading to growth hormone deficiency, thyroid dysfunction, or early onset of conditions like diabetes and obesity. Bone health can suffer too, with survivors experiencing shorter stature, weaker bones, and joint damage depending on what treatments they received and at what age.
Hearing loss from certain chemotherapy agents, cataracts and dry eyes from radiation, lung scarring, kidney problems, dental abnormalities, and a weakened immune system round out a long list of potential late effects. Because of these risks, childhood cancer survivors typically need specialized follow-up care that continues well into adulthood, with screening schedules tailored to the specific treatments they received.